"In the first part of the study [with 75 patients], the cohort receiving two doses via intradermal (vs. intramuscular) vaccination, 13/13 subjects produced strong anti-ebola antibody responses. The second stage of the study will evaluate number of doses, lower doses and a combination with DNA-based IL-12," Kolbert wrote in an Aug. 11 research report.
"The intradermal approach is also being evaluated for Inovio's Zika vaccine, now in a human study," Kolbert wrote.
While Kolbert acknowledges that Inovio's Ebola, Zika and MERS programs continue to make progress, "our focus remains on VGX-3100 and the start of the pivotal program, hopefully by YE16." VGX-3100 targets cervical dysplasia.
On Aug. 16, Inovio announced it had licensed a veterinary vaccine for foot and mouth disease (FMD) to South Korean firm Plumbline Sciences. "Plumbline will fund all development activities for this FMD vaccine," Inovio's press release states. Inovio will receive "milestone payments" and royalties on sales in Asia, excluding Japan, according to the release.
The licensing agreement, Inovio's second with Plumbline, enables the company to "focus on human immunotherapies to fight cancers and infectious diseases, we want to monetize non-core assets," according to CEO Dr. J. Joseph Kim.
Inovio has also released its Q2/16 financial results; details are available here.
Read what other experts are saying about:
Want to read more Life Sciences Report interviews like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent interviews with industry analysts and commentators, visit our Streetwise Interviews page.
Disclosure:
1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She owns, or her family owns, shares of the following companies mentioned in this article: None.
2) The following companies mentioned in this article are sponsors of Streetwise Reports: Inovio Pharmaceuticals Inc. The companies mentioned in this article were not involved in any aspect of the article preparation. Streetwise Reports does not accept stock in exchange for its services. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their families are prohibited from making purchases and/or sales of those securities in the open market or otherwise during the up-to-four-week interval from the time of the interview or article until after it publishes.
Additional disclosures about the sources cited in this article
